Ibogaine as a Treatment for Substance Misuse: Potential Benefits and Practical Dangers
AI-extracted · unverified · confirm at source
Most comprehensive fatality review: 33 ibogaine-associated deaths (1990–2018); mean age 39.5; 26/33 opioid detoxification; cardiac disease in ≥6; co-intoxicants in ≥12; 1:427 death-to-treatment ratio (8 ibogaine-contributory of 11 total).
Dosing: variable/unknown — retrospective review of 33 fatalities; therapeutic range 500–1000 mg (10–25 mg/kg); post-mortem blood levels 0.24–9.3 mg/L (oral)
Safety data present: QTC
Contraindications: Pre-existing cardiac disease (MI, cardiomyopathy, bradyarrhythmia), QTc prolongation, Liver disease (cirrhosis, fibrosis), Schizophrenia or psychosis, Recent or concurrent opiate use, Recent or concurrent stimulant use, Concurrent hallucinogen use (e.g., ayahuasca), CYP2D6 poor metaboliser phenotype, Pulmonary embolism risk factors (immobility, IV drug use history), Alcohol withdrawal seizure risk